Age-Related Macular Degeneration


Neovascular Age-Related Macular Degeneration (also known as “wet” AMD) is the most prevalent cause of severe vision less in the elderly.  This condition affect more than 1.75 million people in the United States and more than 12 million people worldwide.  Due to the aging population, the incidence of Neovascular Age-Related Macular Degeneration is forecasted to increase by 50% by the year 2020.  Current therapies are ineffective for some patients and the frequent injections required are a burden and carry a safety risk for all patients.  AsclepiX Therapeutics addresses this in two main ways:

  • A peptide drug agent that blocks both VEGF and non-VEGF signaling and can cause both inhibition of new neovasculature as well as regression of existing vasculature.
  • A delivery system that ensures long-term controlled release of the peptide drug over time.